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Abstract  
It remains unclear in adult acute myeloid leukemia (AML) whether leukemic expression of 
CD33, the target antigen for Gemtuzumab Ozogamicin (GO), add prognostic information on 
GO effectiveness at different doses. CD33 expression quantified in 1583 patients recruited to 
UK-NCRI-AML17 (younger adults) and UK-NCRI-AML16 (older adults) trials was 
correlated with clinical outcomes and benefit from GO including a dose randomisation. CD33 
expression associated with genetic subgroups, including lower levels in both adverse 
karyotype and core-binding factor (CBF)-AML, but was not independently prognostic. When 
comparing GO versus no GO (n=393, CBF-AMLs excluded) by stratified subgroup-adjusted 
analysis, patients with lowest quartile (Q1) %CD33-positivity had no benefit from GO 
(relapse risk, HR 2·41[1·27–4·56], p=0·009 for trend; overall survival, HR 1·52[0·92–2·52]). 
However from the dose randomisation (NCRI-AML17, n=464, CBF-AMLs included), 
6mg/m2 GO only had a relapse benefit without increased early mortality in CD33-low (Q1) 
patients (relapse risk HR 0·64[0·36–1·12] versus 1.70[0.99-2.92] for CD33-high, p=0·007 
for trend). Thus CD33 expression is a predictive factor for GO effect in adult AML; although 
GO does not appear to benefit the non-CBF AML patients with lowest CD33 expression a 
higher GO dose may be more effective for CD33-low but not CD33-high younger adults. 
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Introduction  
The modest improvement with conventional cytotoxic therapies in the majority of acute 
myeloid leukemia (AML) patients provides an opportunity for immunotherapeutic strategies 
for treating this disease. Expression of CD33 is a feature of most AMLs and has been 
exploited for immuno-targeting using gemtuzumab ozogamicin (GO), a CD33-directed 
antibody-drug conjugate (ADC) that has served as a paradigm for antigen-specific 
immunotherapy of cancer.
1
 When combined with intensive chemotherapy GO significantly 
improves outcomes in newly diagnosed adult AML,
2-6
 and studies demonstrate the 
importance of appropriately defining patient subgroups that may most benefit from this 
therapy. A meta-analysis of 3325 adult patients, who did not require to be CD33 positive, in 5 
randomised controlled trials of GO combined with intensive chemotherapy, showed that GO 
significantly reduced relapse risk and improved overall survival.
7
 The greatest benefit was 
observed in patients with favourable-risk cytogenetics although significant benefit was also 
observed for intermediate-risk patients. No benefit was observed from the addition of GO in 
patients with adverse-risk disease. The meta-analysis appeared to show equivalent outcomes 
in all genetic subgroups from the lower dosage of GO compared to the higher dose with 
single dose schedules. This GO-derived reduced relapse risk is also observed when added to 
intensive chemotherapy in pediatric AML
8
 though associations with risk group are less clear 
in these patients.  
A key parameter for the potential efficacy of an ADC may be expression levels of the 
targeted antigen on leukemic cells as this will determine how much of the conjugate will 
bind. In AML, CD33 blast expression is heterogeneous between patients but there has been 
uncertainty of the clinical importance of this for GO effectiveness since CD33 expression 
levels are associated with established prognostic factors including genetic subgroups. Higher 
CD33 expression is a feature of patients with FLT3-ITD mutation or NPM1 mutation,
9-12
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while low CD33 expression is characteristic of core-binding factor (CBF) -AML in pediatric 
patients 
9,11
 although, perhaps paradoxically, the CBF-AML subgroup derived the most 
benefit from GO in adult trials. Furthermore CD33 expression may potentially be a 
prognostic factor independently of these genetic associations as observed in pediatric AML.
11
  
Results from the Children’s Oncology Group (COG) AML trials showed that benefit from 
GO at a single dose of 3mg/m
2 
at first induction and then intensification 
9 
was restricted to 
pediatric patients with high CD33 blast expression; this was also true for CBF-AMLs. High 
CD33 also correlated with response to GO in the French ALFA-0701 older adult cohort in 
which a higher cumulative dose of GO at induction (sequential schedule of 3mg/m
2
) was 
administered with standard chemotherapy.
10
 Notwithstanding these data it remains unclear 
whether CD33 expression is independently predictive of GO benefit in adults and how this 
might compare at different doses of GO.  
The most recent UK- National Cancer Research Institute (NCRI) -AML trials of younger 
(NCRI-AML17) and older (NCRI-AML16) adult patients included standard induction 
chemotherapy randomised with or without a single dose of GO, a GO dose randomisation 
(NCR-AML17 only) and an assessment of CD33 expression by AML blasts in the pre-
treatment sample. We thus performed a retrospective analysis of CD33 expression on the GO 
treatment effect in a large cohort of these patients 
 
Methods 
Study Cohort 
The NCRI-AML16 (ISRCTN11036523) and NCRI-AML17 (ISRCTN55675535) trials 
enrolled patients with AML (de novo or secondary) or high-risk myelodysplastic syndrome 
(MDS); patients were mostly aged ≥60 years in NCRI-AML16 and mostly aged <60 years 
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old in NCRI-AML17 (protocols in supplementary information ; Figures S1-S2). In both trials 
CD33-positivity was not an entry requirement and patients were randomised into intensive 
chemotherapy arms with or without a single dose of GO in course 1 of induction. In NCRI-
AML16 GO was given at 3mg/m
2
, while in NCRI-AML17 patients were randomised to 
receive either 3mg/m
2
 or 6mg/m
2
 of GO. Trials were conducted in accordance with the 
Declaration of Helsinki and both institutional and research ethics committee approvals were 
obtained. Data regarding chemotherapy interventions
13
 and dose comparisons
14
 are published 
separately. Acute promyelocytic leukemia (APML) patients and patients <16 years were 
excluded from this analysis. 
Flow cytometric assessment of CD33 expression 
CD33 expression of AML blasts from 1583 pre-treatment BM/PB samples of non-APML 
patients (NCRI-AML16, n=334; NCRI-AML17, n=1249, patient deployment shown in 
Figure 1) was prospectively determined by multiparameter flow cytometry (MFC). Staining 
and data acquisition were performed by three national reference flow cytometric laboratories 
sharing standard operating procedures,
14
 and then centrally analysed for CD33 blast 
expression without knowledge of other clinical data for retrospective correlation with clinical 
characteristics and outcome.  
AML blast CD33 expression was measured both by median fluorescence intensity of CD33 
(CD33-MFI) and also as percentage (%) CD33-positivity (gating described in supplemental 
methods). CD33-MFI was also measured for the immunophenotypically immature 
CD34
+
CD38
low
 stem/progenitor cell (SPC) population when present. The CD33-MFI values 
in each patient were standardized using the CD33-MFI values of lymphocytes (uniformly 
CD33 negative) present within the same sample. %CD33-positivity was also determined 
using lymphocytes in each sample; blast cells with CD33 expression equivalent to 
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lymphocytes were classed as CD33

 and blasts with higher expression were classed as CD33
 
(Figure S3). A broad range of CD33-MFI and %CD33-positivity values were observed and so 
patients were grouped into quartiles (Q1, Q2, Q3, Q4) for both type of measurements.  
 
Statistical methods  
Clinical outcome data up to March 2015 for patients enrolled on NCRI-AML16 and NCRI-
AML17 were analysed with median follow up of 40.7 months (range 1·2–71·4 months) 
(AML16 41·8 months (1·3–67·4), AML17 39·7 months (1·2–71·4)). Endpoint definitions are 
as described by Cheson with the exception that we report here overall response rate (ORR; 
CR+CRi, i.e. recovery is not required).
15
 Demographic data were compared using the 
Wilcoxon rank-sum/Kruskal Wallis test or Spearman’s correlation, or chi-squared/Mantel-
Haenszel test for the dichotomous outcome of CD33

 or CD33

. Agreement between local 
and central measurement of CD33 was performed using Bland-Altman plots. Univariate 
analyses of time to event outcomes were performed using the logrank test; multivariable 
adjusted analyses were performed using Cox regression. Analysis of the effect of GO 
treatment was performed stratified by trial as the randomisation was 1:1 in AML16 and 2:1 in 
AML17, and data displayed using Forest plots. In all cases, estimates of odds/hazard rations 
(OR/HR) are given with 95% confidence intervals. Analyses were performed using SAS 
version 9.3. In addition to overall analyses, exploratory analyses were performed stratified by 
the randomisation stratification parameters and other important variables, with suitable tests 
for interaction. Because of the well-known dangers of subgroup analysis, these were 
interpreted cautiously. 
 
Results 
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CD33 expression and correlations with disease characteristics 
Patients from the two trials were divided into quartiles based on CD33-MFI (inter-quartile 
cut-points; 3·52, 8·71, 19·66) or quartiles based on %CD33-positivity of the total blast 
population (inter-quartile cut-points; 37·1%, 75·8%, 94·9%). A non-linear correlation 
between these two parameters was observed and overlap of quartiles (Figure S4). There was 
poor agreement between our %CD33-positivity data (acquired by the reference laboratories 
and centrally analysed) and that acquired and entered into trial database by local laboratories   
(Figure S5).  
Disease characteristics were then assessed across the CD33 quartiles. Cytogenetic data was 
available for 1454 of 1583 patients (92%). Corroborating the published data, CBF-AML was 
found to be inversely correlated with CD33 expression across the quartiles (p<0·0001, Figure 
2a-b; Table 1). However, in this adult cohort adverse-risk disease was also associated with 
lower CD33 expression (p<0·0001, Figure 2a-b). Intermediate-risk cytogenetics significantly 
increased in prevalence with increasing CD33 quartile (p<0·0001, Figure 2a-b). While FLT3-
ITD and NPM1 mutations increased in prevalence with increasing CD33 expression 
(p<0·0001, Figure 2c-d; Table 1), as already reported,
9-11
 intermediate-risk patients lacking 
these mutations were inversely associated with CD33 expression. All the above correlations 
were observed using either CD33-MFI or %CD33-positivity as the assessment variable. 
In addition to total AML blasts, we also assessed CD33 expression in immunophenotypically 
immature CD34

CD38low blasts, which are enriched for chemo-resistant leukemic stem-cell 
(LSC) –like populations in some patients. This analysis was performed on all patients with 
detectable CD34

CD38
low
 blasts (n=1301), and then focussed on patients with significantly 
expanded CD34

CD38
low
 blasts (n=779) using a threshold of greater than 0·35% of total 
WBC (>2SD above mean normal frequency) to exclude patients with immature blasts that 
©    2016 Macmillan Publishers Limited. All rights reserved.
Page 9 of 22 
 
may be predominantly non-leukemic. As with total blasts there was considerable variation in 
CD33 expression on immature blasts across the cohort (Table S1). We classified patients with 
expanded CD34
+
CD38
low
 cells into CD33

 (Q1) and CD33
+
 (Q2-Q4), under the supposition 
that CD33

 cells represent a GO-unresponsive subpopulation, and thus may have prognostic 
value. Comparison between patient sub-groups showed that expanded CD34

CD38
low
 blasts 
in CBF-AMLs were almost always CD33

 (in Q2-Q4), while in both intermediate-risk and 
adverse-risk patients the CD34

CD38
low
 blasts were more heterogeneous, containing 
significant numbers of CD33
 
cells (Q1) (Figure 2c). Patients with CD33

 CD34

CD38
low
 
blasts showed a trend of increased prevalence of FLT3-ITD mutation (16% vs 7%, p=0·03) 
and NPM1 mutation (12% vs 6%, p=0·1) (Table S1). 
 
CD33 expression and clinical outcomes 
In an analysis adjusted for trial, there was no significant difference in outcomes between 
patients with and without CD33 data (p=0·4). Higher CD33 expression, by either 
measurement, showed significant positive prognostic value in univariate analyses for both 
overall survival (OS) and cumulative incidence of relapse (CIR) (Table 2). This did not 
remain significant, however, after adjustment in multivariable analysis for cytogenetics, age, 
log-WBC, performance status, FLT3-ITD mutation, NPM1 mutation, secondary disease and 
trial protocol, (OS; HR 1·01 [0·93–1·09], p=0·8 using CD33-MFI and HR 1·01 [0·94–1·09], 
p=0·8 using % CD33-positivity, CIR; HR 0·99 [0·91–1·08], p=0·8 using CD33-MFI and HR 
1·00 [0·91–1·09], p=0·9 using %CD33-positivity, Table 2). Therefore, in contrast to pediatric 
AML, CD33 expression on blasts is not independently prognostic for outcomes in our adult 
cohort. This was also the case when the analysis was limited to the 1077 patients who did not 
receive GO (Table S2). In NCRI-AML17 all CBF-AML patients received GO during 
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induction. There was no evidence of a significant association between CD33 expression 
quartiles and outcomes in this subgroup (Figure S6) although this does not exclude that CD33 
expression may be prognostic for CBF-AML patients not receiving GO. Perhaps surprisingly 
patients with expanded CD34
+
CD38
low
 blasts that were CD33

 had improved OS both in the 
overall cohort (HR 0·61 [0·45–0·84] p=0·002; Table S3a) and when patients receiving GO 
were excluded (HR 0·73 [0·44-1·01] p=0·05; Table S3b). 
 
CD33 expression and impact on GO-sensitivity 
We then asked whether CD33 expression was relevant to benefit in outcomes observed in 
patients receiving GO with their induction chemotherapy compared with patients receiving 
chemotherapy alone (GO vs no GO). 393 patients across the two trials were assessable for 
this GO vs no GO comparison with CBF-AMLs excluded as these were all given GO in 
AML17 and there were only two CBF-AMLs in AML16. A total of 244 patients received GO 
(AML16 n=42, all allocated 3mg/m
2
, AML17 n=202 at either 3mg/m
2
 (n=100) or 6mg/m
2 
(n=102); Figure 1) (In AML17, patients receiving DA were not randomised between GO and 
no GO – all received GO at either 3mg/m2 or 6mg/m2). The results showed no evidence of 
significant interaction between GO and CD33 quartiles on survival, using either CD33 
parameter (Figure 3a). When evaluating relapse, however, there was a significant interaction 
between GO and %CD33-positive blasts (p=0·009 for trend). Patients with the lowest 
%CD33-positive blasts (Q1) had a significantly greater relapse risk when given GO (HR 2·41 
[1·27–4·56]) while patients with the highest %CD33-positive blasts (Q4) showed reduced 
relapse risk (HR 0·63 [0·35–1·12]) (Figure 3b). This differential benefit was not observed 
using blast CD33-MFI (Figure 3b). 
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 Having established CD33 expression was relevant to effect of GO on relapse, we then 
assessed for difference in outcomes by CD33 expression in 464 patients entering the AML17 
GO dose randomisation (3mg/m
2
, n=239; 6mg/m
2
, n=225; Figure 1). Stratification of patients 
by CD33 expression quartiles showed a differential benefit by GO dose for relapse (Figure 
4a) but not for OS (Figure 4b). Using %CD33-positivity, patients with lowest CD33 
expression (Q1) had most benefit from the higher 6mg/m
2
 dose of GO (p=0·007 for trend) 
(Figure 4a). Importantly, there was no excess early (60-day) mortality from the 6mg/m
2
 dose 
in these patients (Figure 4c). Patients with the highest %CD33-positive blast levels (Q4) did 
not benefit from the higher dose (relapse, HR 1·70 [0·99–2·92]) (Figure 4a).  
As expanded CD34
+
CD38
low
 blasts in CBF-AMLs were almost always CD33
+
, we 
hypothesized this might contribute to greater GO efficacy in CBF-AMLs as clearance of 
potential LSCs in the CD34
+
CD38
low 
subset by GO would not be limited by their low CD33 
expression. An exploratory subgroup analysis of non-CBF AML patients in the GO versus no 
GO and GO dose randomisations did not show a significant interaction between GO 
treatments and CD33

 versus CD33

 expanded CD34

CD38
low
 blasts (Figure S7).  
 
Discussion 
In this report, we assessed the importance of CD33 expression in a large cohort of adult AML 
patients that included randomisations to receive standard chemotherapy alone or in 
combination with a single dose of GO at 3mg/m
2
 or 6mg/m
2
. 
Greater efficacy of GO in patients with higher expression of the target antigen is logical and 
supported by in vitro data showing a direct relationship between CD33 expression and GO-
sensitivity,
16
 and clinical data from GO monotherapy in relapsed AML patients
17
 and older 
patients deemed unfit for intensive chemotherapy.
18
 Very recent data has emerged from the 
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COG and French ALFA trials that pediatric and older (50-70 years) AML patients with lower 
CD33 expression do not benefit from the addition of GO to standard chemotherapy (3mg/m
2 
single dose at induction I and intensification II in COG trial, 3mg/m
2 
fractionated doses at 
induction I plus single dose at consolidation for ALFA-0701).
9-10 
In these studies CD33 
expression was measured using % positivity and MFI respectively. We assessed CD33 using 
both types of measurement sub-divided by quartiles rather than a single threshold value in 
order to evaluate prognostic and response correlations for the range of blast CD33 expression. 
CD33 expression data for this study were acquired by reference laboratories and analysed 
centrally. The discrepancy between these data and analyses  from local laboratories primarily 
classifying AML blasts as CD33 positive or negative 
2,3
 highlights the value of standardised 
analysis for flow cytometric biomarkers that input into trial data. Interestingly our non-linear 
concordance profile of these measurements (Figure S2) is similar to that of the ALFA group
10
 
despite the inevitable differences of instrumentation as well as reagents and blast gating 
between studies. This further validates these CD33 biomarker assays as reproducible and 
practical in different centers but also shows that CD33MFI and %CD33-positivity are not 
equivalent for some patients since higher %CD33 values are included in CD33-MFI lower 
quartiles. Notwithstanding we observed similar associations for both expression parameters 
with patient disease characteristics such as cytogenetics and molecular aberrations (FLT3-
ITD and NPM1 mutations). From our adult cohort adverse karyotype, wild type FLT3 / 
NPM1 as well as CBF-AML are all associated with lower CD33 expression. We also 
demonstrate an independent correlation between %CD33-positivity and GO benefit for 
younger and older adults with non-CBF AML.  
The recent COG data similarly describes an association between CD33 expression (by a 
different CD33-MFI assay) and GO response in their pediatric AAMLL0531 cohort 
9
 that 
included ~25% CBF AMLs. It appears that there was a relatively higher frequency of CBF-
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AMLs with low CD33 expression (~45% of CBFs in Q1) enrolled in their trial than in our 
adult cohort (~29% of CBFs in Q1, Table 1). Since CD33-low patients derive the least 
benefit from GO, this may plausibly contribute to why the significant association of GO 
benefit with CBF-AML reported from adult studies has not been demonstrated for this COG 
cohort.
8
 
In this study all CBF-AML patients included in the analysis received GO (3mg/m
2 
or 
6mg/m
2
) at induction, thus excluding an analysis of GO versus no GO stratified by CD33 
expression quartiles. There was however no significant correlation between CBF CD33 
expression and outcome suggesting that other factors could be important for the relative GO 
sensitivity of this subgroup in adults. Alternatively GO exposure may differentially 
counteract any negative prognostic impact from for example higher CD33 expression (as 
suggested by COG data 
9,11
) in CBF-AMLs. 
Our analysis also defined CD33 expression in the immunophenotypically immature 
CD34
+
CD38
low
 blast population, which is often expanded in AML and reported as clinically 
and experimentally relevant for treatment responses.
19-21
 Previous data have shown that high 
CD33 expression by such cells enhances their GO sensitivity.
22
 Interestingly, expanded 
immature blasts in CBF-AMLs were almost exclusively CD33

 despite lower CD33 
expression of the global blast population. Conversely, there was variable CD33 expression on 
expanded CD34

CD38
low
 blasts in intermediate-risk and adverse-risk patients. CD33-
positivity of this candidate LSC- enriched population may allow effective antigen-specific 
targeting and clearance of potentially more chemo-resistant subpopulations in CBF-AMLs. 
Our results however did not show a significant interaction between CD33 status of expanded 
CD34

CD38
low
 blasts in non-CBF AML patients and GO response. This is not unexpected 
due to the confounding variables of heterogeneous CD33 expression in the main blast 
population between patients and other biological factors for GO resistance. 
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The clinical trials of combined chemotherapy with GO, mentioned earlier, used different 
doses and schedules of GO, however the meta-analysis of the individual patient data from 
these trials suggested a single dose of 3mg/m
2
 was as effective at preventing relapse as a 
6mg/m
2
 dose, while having less toxicity. The NCRI-AML17 trial included a 6mg/m
2
 vs 
3mg/m
2
 randomisation to ascertain whether efficacy was enhanced by the higher dose. 
Results overall showed no significant benefit and a higher rate of veno-occlusive disease with 
the higher dose although there was trend for improved outcomes in the adverse karyotype 
patients.
23
 Our analysis using CD33 as a stratification variable showed a significant 
interaction between dose and %CD33-positivity in NCRI-AML17 patients (younger adults); 
the higher 6mg/m
2
 dose of GO most improved relapse risk and was well tolerated by patients 
with the lowest CD33 expression. Conversely, patients with higher CD33 levels 
independently of risk group do not appear to derive any additional benefit from increasing the 
dose from 3mg/m
2
 to 6mg/m
2
 as single induction dose. This is the first demonstration of a 
pre-treatment biomarker that could inform appropriate use of a higher GO dose (and 
potentially other CD33-targeted antibody conjugates) at induction and suggests that the 
6mg/m
2
 dose benefit for adverse-risk AML outcomes may be specific to patients with Q1-
CD33 expression. These findings have to be interpreted however within the recognised 
limitations of potential false-positives from subgroup analysis. Moreover it is as yet uncertain 
whether the higher dose improves GO chemosensitivity for patients with co-association of the 
multidrug resistance phenotype and CD33-low expression 
17 
or HFE mutations.
24
 
Further optimisation of treatment schedules in ongoing trials includes a single GO dose 
versus fractionated GO dose comparison (NCRI-AML18/19). Interestingly from the ALFA-
0701 data the fractionated GO schedule (3mg/m
2 
on day 1, maximum dose: 5mg) did not 
improve outcome in older adults with lower CD33 expression. Although this may imply that 
a single higher 6mg/m
2
dose is more effective than a cumulative higher dose at reducing 
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relapse in the CD33-lower subgroup, our data  is restricted to younger adults and therefore 
may not be relevant to the older age group.   
Next-generation CD33-directed ADC including SGN-CD33A are reported to be more potent 
than GO, without liver toxicity
25 
and may also be more active in multidrug resistance.
26
 The 
results of our study suggest that assessment of CD33 expression in trials using these next-
generation CD33-directed ADCs will be important to inform future optimal dosing.  
Ultimately, this could lead to a more personalized mode of GO treatment based on patient 
AML blast CD33 expression. 
 
Supplementary information accompanies this paper on the Leukemia website 
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Figure Legends 
Figure 1 
Outline of AML patient sample flow for CD33 assessment using pre-treatment samples from 
NCRI-AML16 and NCRI-AML17. CBF, core-binding factor. GO, gemtuzumab ozogamicin. 
 
Figure 2 
AML blast CD33 expression in patient subgroups 
CD33 expression of pre-treatment AML blasts by normalised CD33-MFI (arbitrary units) and 
% positivity in cytogenetic risk groups (A) and intermediate-risk patients subdivided based 
on mutational (FLT3-ITD and NPM1) background (B). Expanded CD34

CD38
low
 blasts 
(when at least 0·35% of total WBC) classified as CD33

 (Q1 CD33-MFI) or CD33

 (Q2-Q4 
CD33-MFI) assessed in cytogenetic risk groups and mutational groups (C). 
 
Figure 3 
Effect of CD33 expression levels on (A) overall survival and (B) relapse in GO versus no GO 
randomised AML patients 
Forest plot analysis of 393 non-CBF patients assessable for GO vs no GO comparison. 
Patients were stratified into CD33 expression quartile using CD33-MFI and %CD33-
positivity.  
 
Figure 4 
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Effect of CD33 expression levels on (A) relapse, (B) overall survival and (C) early mortality 
(60 days) in patients randomised to receive 6mg/m
2
 or 3mg/m
2
 GO dose  
Forest plot analysis of 464 younger patients (NCRI-AML17 trial) assessable for GO vs no 
GO comparison. Patients were stratified into CD33 expression quartile using CD33-MFI and 
%CD33-positivity. 
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Table 1: Patient demographics and CD33 expression levels by CD33 MFI and %CD33 positivity
Trial                                   
AML16
AML17 100 (26%) 60 (16%) 64 (17%) 75 (19%) 105 (27%) 71 (18%) 78 (20%) 80 (20%)
286 (74%) 326 (84%) 323 (83%) 311 (81%) 290 (73%) 325 (82%) 319 (80%) 315 (80%)
Randomisation† 
(AML16/AML17)
                     GO 39 (42%) 26 (33%) 33 (32%) 51 (43%) 39 (42%) 34 (34%) 36 (40%) 40 (36%)
No GO 53 (58%) 54 (68%) 69 (68%) 67 (57%) 54 (58%) 65 (66%) 55 (60%) 70 (64%)
GO dose (AML17)
 GO 3mg/m
2 41 (47%) 54 (50%) 63 (50%) 79 (56%) 54 (54%) 55 (45%) 60 (55%) 70 (53%)
GO 6mg/m
2 46 (53%) 54 (50%) 62 (50%) 62 (44%) 46 (46%) 68 (55%) 50 (45%) 61 (47%)
Age at diagnosis, y
     16-29 25 (6%) 44 (11%) 39 (10%) 41 (11%) 25 (6%) 34 (9%) 50 (13%) 41 (10%)
     30-39 25 (6%) 39 (10%) 35 (9%) 30 (8%) 28 (7%) 36 (9%) 36 (9%) 30 (8%)
     40-49 48 (12%) 75 (19%) 67 (17%) 98 (25%) 53 (13%) 73 (18%) 84 (21%) 78 (20%)
     50-59 106 (27%) 107 (28%) 127 (33%) 109 (28%) 106 (27%) 125 (32%) 105 (26%) 115 (29%)
     60-69 139 (36%) 97 (25%) 100 (26%) 82 (21%) 136 (34%) 103 (26%) 95 (24%) 106 (27%)
70+ 43 (11%) 24 (6%) 19 (5%) 26 (7%) 47 (12%) 25 (6%) 27 (7%) 25 (7%)
median (range) 59 (16-79) 54 (16-78) 54 (16-79) 52 (16-77) 59 (16-79) 54 (16-79) 52 (16-77) 54 (17-79)
Sex                                       
Female 154 (40%) 160 (41%) 172 (44%) 201 (52%) 149 (39%) 178 (45%) 181 (46%) 192 (49%)
     Male 232 (60%) 226 (59%) 215 (56%) 185 (48%) 246 (62%) 218 (55%) 216 (54%) 203 (51%)
Diagnosis
De Novo 300 (78%) 331 (86%) 320 (83%) 344 (89%) 311 (79%) 322 (81%) 339 (85%) 352 (89%)
Secondary 49 (13%) 32 (8%) 46 (12%) 31 (8%) 50 (13%) 44 (11%) 39 (10%) 31 (8%)
MDS 37 (10%) 23 (6%) 21 (5%) 11 (3%) 34 (9%) 30 (8%) 19 (5%) 12 (3%)
WHO PS
0 250 (65%) 265 (69%) 259 (67%) 257 (67%) 264 (67%) 273 (69%) 256 (64%) 267 (68%)
1 114 (30%) 104 (27%) 111 (29%) 116 (30%) 112 (28%) 104 (27%) 121 (30%) 115 (29%)
2 17 (4%) 12 (3%) 10 (3%) 7 (2%) 14 (4%) 11 (3%) 13 (3%) 10 (3%)
3 5 (1%) 4 (1%) 7 (2%) 6 (2%) 5 (1%) 7 (2%) 7 (2%) 3 (1%)
0·7** 0·6**
<·0001** <·0001**
0·0004* 0·001*
0·0001* <·0001*
0·005* 0·08*
395 396 397 395
Q1 Q2 Q3 Q4 p-value
No of patients 386 386 387 386
%CD33 positivity
p-value
CD33 MFI normalised blasts
Characteristic Q1 Q2 Q3 Q4 
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4 0 1 (<.5%) 0 0 0 1 (<.5%) 0 0
WBC count
       0-9.9 257 (67%) 198 (51%) 171 (44%) 155 (40%) 255 (65%) 218 (55%) 183 (46%) 152 (38%)
     10-49.9 93 (24%) 121 (31%) 148 (38%) 136 (35%) 94 (24%) 124 (31%) 132 (33%) 155 (39%)
     50-99.9 13 (3%) 36 (9%) 40 (11%) 53 (14%) 22 (6%) 26 (7%) 50 (13%) 48 (12%)
    100+ 23 (6%) 31 (8%) 28 (7%) 42 (11%) 24 (6%) 28 (7%) 32 (8%) 40 (10%)
Median (range) 4·9 9·2 12·8 16·4 5·1 7·2 12·7 16·6 
(0·4-430·0) (0·4-334·9) (0·6-249·0) (0·7-345·0) (0·4-430·0) (0·6-334·9) (0·7-266) (0·7-345·0)
Cytogenetics
Favourable 54 (16%) 74 (21%) 40 (11%) 18 (5%) 48 (14%) 88 (24%) 41 (11%) 10 (3%)
Intermediate 203 (59%) 219 (61%) 254 (70%) 308 (87%) 214 (61%) 211 (57%) 270 (72%) 312 (87%)
Adverse 87 (25%) 66 (18%) 71 (19%) 28 (8%) 90 (26%) 71 (19%) 62 (17%) 36 (10%)
Unknown 42 27 21 32 43 25 24 37
FLT3-ITD
WT 303 (93%) 295 (86%) 289 (81%) 235 (67%) 315 (92%) 315 (88%) 294 (82%) 230 (65%)
Mutant 22 (7%) 48 (14%) 66 (19%) 116 (33%) 27 (8%) 43 (12%) 64 (18%) 122 (35%)
Unknown 61 43 32 35 53 38 39 43
NPM1c
WT 299 (95%) 272 (80%) 231 (67%) 148 (44%) 316 (95%) 291 (83%) 220 (64%) 155 (46%)
Mutant 16 (5%) 66 (20%) 112 (33%) 188 (56%) 17 (5%) 61 (17%) 125 (36%) 185 (54%)
Unknown 71 48 44 50 62 44 52 55
ITD/NPM1c
ITD WT, NPM1c WT 281 (89%) 248 (74%) 205 (60%) 116 (35%) 295 (89%) 271 (78%) 197 (57%) 115 (34%)
ITD WT, NPM1c Mut 11 (4%) 41 (12%) 73 (21%) 110 (33%) 9 (3%) 36 (10%) 85 (25%) 109 (32%)
ITD Mut, NPM1c WT 17 (5%) 22 (7%) 26 (8%) 32 (10%) 19 (6%) 17 (5%) 23 (7%) 40 (12%)
ITD Mut, NPM1c Mut 5 (2%) 25 (7%) 39 (11%) 77 (23%) 8 (2%) 25 (7%) 40 (12%) 75 (22%)
Unknown 72 50 44 51 64 47 52 56
Post-course 1 risk score 
(AML17)
Good 50 (20%) 80 (27%) 44 (15%) 39 (13%) 47 (18%) 86 (28%) 55 (18%) 26 (9%)
Standard 88 (34%) 118 (39%) 147 (49%) 186 (62%) 91 (35%) 111 (36%) 163 (54%) 176 (59%)
Poor 118 (46%) 103 (34%) 112 (37%) 73 (25%) 118 (46%) 108 (35%) 85 (28%) 95 (32%)
0·04** 0·2**
<·0001* <·0001*
<·0001* <·0001*
<·0001* <·0001*
0·7** 0·6**
<·0001** <·0001**
0·4** 0·7**
*: Wilcoxon-Rank Sum/Kruskal-Wallis test; **: Spearman correlation; †: excluding CBF leukaemia (AML16 n=2, AML17 n=46); 
Abbreviations: GO=gemtuzumab ozogamicin, WHO PS=World Health Organisation performance score, WBC=white blood cell, FLT3-
ITD=FLT3 internal tandem duplication, WT=wild type; Mut=mutated, MFI=median fluorescence intensity.
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Table 2: Clinical outcomes and CD33 expression
0·75 (0·66–0·85) p<·0001; 0·78 (0·69–0·88) p<·0001;
0·81 (0·68–0·96) p=0·02 0·86 (0·73–1·02) p=0·08
0·90 (0.85–0·95) p=0·0005;
0·90 (0·85–0·96) 
p=0·0007;
1·01 (0·93–1·09) p=0·8 1·01 (0·94–1·09) p=0·8
0·93 (0·86–0·99) p=0·03; 0·91 (0·85–0·98) p=0·01;
0·99 (0·91–1·08) p=0·8 1·00 (0·91–1·09) p=0·957% 55%CIR 56% 54% 49% 50% 50%
Q4 
50%
35% 40% 45%
OR/HR, 95% CI, p-value 
unadjusted/adjusted
87%
OS 27% 36% 37% 48% 27%
CR/CRi 79% 80% 87% 89% 76% 85% 85%
%CD33 positivity
OR/HR, 95% CI, p-value 
unadjusted/adjusted
CD33 MFI normalised blasts
Outcome Q1 Q2 Q3 Q4 Q1 Q2 Q3 
Note: Adjusted OR/HR for age, cytogenetics, trial, log (WBC), secondary disease, ITD, NPM1. OR/HR presented 
per quartile.
Abbreviations: CR=complete remission, CRi=complete remission with incomplete blood count recovery, 
OS=overall survival, CIR=cumulative incidence of relapse, MFI=median fluorescence intensity, OR=odds ratio, 
HR=hazard ratio, CI=confidence interval.
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Figure 1
Outline of AML patient sample flow for CD33 assessment 
Poor sample with insufficient blasts 
(n=75; 5%)
Patients with valid CD33 expression data
(n=1583; AML16 n=334, AML17 n=1249)
Non-APML adult patients screened for 
surface CD33 expression (n=1658)
GO vs no GO randomisation 
AML16 & AML17 (n=393; 25%) 
(excluding CBF-AMLs)
no GO (n=149)
(AML16 n=54
AML17 n=95)
GO  (n=244)
(AML16 n=42; all 3mg/m2)
(AML17 n=202; 3mg/m2 n=100, 
6mg/m2 n=102)
GO 3mg/m2
(n=239)
GO 6mg/m2
(n=225)
GO dose randomisation
AML17 only (n=464; 37%)
CBF-AMLs included
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Figure 2
Distribution of CD33 expression with cytogenetic and mutational characteristics of AML patients 
A
B
C
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Figure 3:  Effect of CD33 expression levels on outcomes in GO versus no GO randomised AML patients
Figure 3a:  Effect of GO on overall survival stratified by CD33 expression
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Figure 3b:  Effect of GO on relapse stratified by CD33 expression
Figure 3:  Effect of CD33 expression levels on outcomes in GO versus no GO randomised AML patients
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Figure 4a:  Effect of GO dose on relapse stratified by CD33 expression
Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates , 
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose 
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Figure 4b:  Effect of GO dose on survival stratified by CD33 expression
Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates , 
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose 
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Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates , 
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose 
Figure 4c:  Effect of GO dose on early mortality  stratified by CD33 expression
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